Literature DB >> 25937240

Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: a functional imaging study in alcohol dependent subjects.

Patrick Bach1, Sabine Vollsta Dt-Klein2, Martina Kirsch2, Sabine Hoffmann2, Anne Jorde2, Josef Frank3, Katrin Charlet4, Anne Beck4, Andreas Heinz4, Henrik Walter5, Wolfgang H Sommer6, Rainer Spanagel7, Marcella Rietschel3, Falk Kiefer2.   

Abstract

The endogenous opioid system is involved in the pathophysiology of alcohol-use disorders. Genetic variants of the opioid system alter neural and behavioral responses to alcohol. In particular, a single nucleotide polymorphism rs1799971 (A118G) in the mu-opioid receptor gene (OPRM1) is suggested to modulate alcohol-related phenotypes and neural response in the mesocorticolimbic dopaminergic system. Little is known about the clinical implications of these changes. The current study investigated the relationship of genotype effects on subjective and neural responses to alcohol cues and relapse in a sample of abstinent alcohol-dependent patients. Functional magnetic resonance imaging (fMRI) was used to investigate alcohol cue-reactivity and drinking outcome of 81 abstinent alcohol-dependent patients. G-allele carriers displayed increased fMRI cue-reactivity in the left dorsal striatum and bilateral insulae. Neural responses to alcohol cues in these brain regions correlated positively with subjective craving for alcohol and positive expectations of alcohol׳s effects. Moreover, alcohol cue-reactivity in the left dorsal striatum predicted time to first severe relapse. Current results show that alcohol-dependent G-allele carriers׳ increased cue-reactivity is associated with an increased relapse risk. This suggests that genotype effects on cue-reactivity might link the OPRM1 A118G risk allele with an increased relapse risk that was reported in earlier studies. From a clinical perspective, risk-allele carriers might benefit from treatments, such as neuro-feedback or extinction-based therapy that are suggested to reduce mesolimbic reactivity.
Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Alcoholism; Endogenous opioids; OPRM1; Relapse; Single nucleotide polymorphism; fMRI

Mesh:

Substances:

Year:  2015        PMID: 25937240     DOI: 10.1016/j.euroneuro.2015.04.013

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  21 in total

Review 1.  Genetic Similarities between Compulsive Overeating and Addiction Phenotypes: A Case for "Food Addiction"?

Authors:  Nina Carlier; Victoria S Marshe; Jana Cmorejova; Caroline Davis; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2015-12       Impact factor: 5.285

2.  Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.

Authors:  Joseph P Schacht; Patrick K Randall; Patricia K Latham; Konstantin E Voronin; Sarah W Book; Hugh Myrick; Raymond F Anton
Journal:  Neuropsychopharmacology       Date:  2017-04-14       Impact factor: 7.853

3.  The neural correlates of priming emotion and reward systems for conflict processing in alcoholics.

Authors:  T Schulte; Y-C Jung; E V Sullivan; A Pfefferbaum; M Serventi; E M Müller-Oehring
Journal:  Brain Imaging Behav       Date:  2017-12       Impact factor: 3.978

4.  Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism.

Authors:  Caroline A Browne; Rebecca L Erickson; Julie A Blendy; Irwin Lucki
Journal:  Neuropharmacology       Date:  2017-02-07       Impact factor: 5.250

5.  A cis-eQTL in OPRM1 is Associated with Subjective Response to Alcohol and Alcohol Use.

Authors:  Jacqueline M Otto; Ian R Gizer; Joseph D Deak; Kimberly A Fleming; Bruce D Bartholow
Journal:  Alcohol Clin Exp Res       Date:  2017-04-10       Impact factor: 3.455

Review 6.  Neural substrates of cue reactivity: association with treatment outcomes and relapse.

Authors:  Kelly E Courtney; Joseph P Schacht; Kent Hutchison; Daniel J O Roche; Lara A Ray
Journal:  Addict Biol       Date:  2015-10-04       Impact factor: 4.280

Review 7.  Is the Construct of Relapse Heuristic, and Does It Advance Alcohol Use Disorder Clinical Practice?

Authors:  Stephen A Maisto; Katie Witkiewitz; Dezarie Moskal; Adam D Wilson
Journal:  J Stud Alcohol Drugs       Date:  2016-11       Impact factor: 2.582

8.  Elucidating the Effect of a Brief Drinking Intervention Using Neuroimaging: A Preliminary Study.

Authors:  Erica N Grodin; Lara A Ray; James MacKillop; Aaron C Lim; Mitchell P Karno
Journal:  Alcohol Clin Exp Res       Date:  2019-01-20       Impact factor: 3.455

Review 9.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

10.  Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation.

Authors:  Scott H Stewart; Kimberly S Walitzer; Javier Blanco; Denise Swiatek; Linda Paine Hughes; Adolfo Quiñones-Lombraña; Kathleen Shyhalla
Journal:  J Subst Abuse Treat       Date:  2019-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.